CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Mechanical signaling via β2 integrin decouples T cell proliferation and differentiation for generating stem cell-like CAR T cells.
Mechanical signaling via β2 integrin decouples T cell proliferation and differentiation for generating stem cell-like CAR T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
T 细胞受体(TCR)信号下游的增殖与分化程序被认为相互关联,以维持 T 细胞稳态;但这一生物学过程也会导致体外生成的嵌合抗原受体(CAR)T 细胞质量欠佳。本研究显示,纤维蛋白基质介导的机械信号可将增殖与分化程序解耦,从而大量生成未分化、具有干细胞样特征的 CAR(stem-CAR)T 细胞。这些 stem-CAR-T 细胞表达 NANOG、SOX2 和 TCF1,在体外持续杀伤肿瘤细胞,并在乳腺癌、胰腺癌和脑癌实体瘤体内模型中达到最佳疗效。机制上,纤维蛋白基质激活整合素 α2,招募 14-3-3,继而使 Yes 相关蛋白(YAP)磷酸化并失活。YAP 失活解除对转录因子 MafG 的抑制;随后 MafG 激活干性相关基因的转录,促成 stem-CAR-T 细胞生成。这些发现提示,可利用机械信号制备 stem-CAR-T 细胞,或有助于提高 CAR-T 细胞治疗癌症的疗效。
Downstream of T cell receptor (TCR) signaling, proliferation and differentiation programs are thought to be linked to maintain T cell homeostasis. This biology, however, also leads to the in vitro generation of suboptimal chimeric antigen receptor (CAR) T cells.
Here, we show that proliferation and differentiation programs can be decoupled by fibrin matrix-based mechanical signaling, leading to abundant generation of undifferentiated stem cell-like CAR (stem-CAR) T cells. These stem-CAR T cells expressed NANOG, SOX2, and TCF1, exhibited persistent cytolysis in tumor cells in vitro, and achieved optimal efficacy in solid tumor models of breast, pancreatic, and brain cancer in vivo.
Mechanistically, the fibrin matrix activated 2 integrin to recruit 14-3-3 , leading to Yes-associated protein (YAP) phosphorylation and inactivation. Consequently, YAP inactivation derepressed the transcription factor MafG. MafG then transactivated stemness genes, thereby generating stem-CAR T cells.
These findings suggest a mechanical approach to manufacturing stem-CAR T cells, potentially improving CAR T cell therapeutic efficacy for cancer treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。